Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Biotech Powerhouse | Amgen's robust financial health and strategic positioning in key therapeutic areas underscore its potential for sustained growth in the competitive biotechnology landscape |
Obesity Market Gambit | Delve into Amgen's ambitious pursuit of the obesity treatment market with MariTide, a novel bispecific GLP-1 agonist/GIP antagonist in Phase 3 trials |
Pipeline Prowess | Explore Amgen's diverse R&D pipeline, featuring promising candidates in oncology and immunology, poised to drive future revenue growth and market expansion |
Analyst Optimism | Discover why analysts maintain a bullish outlook on Amgen, with price targets ranging from $310 to $346, reflecting confidence in the company's strategic direction |
Metrics to compare | AMGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAMGNPeersSector | |
---|---|---|---|---|
P/E Ratio | 22.3x | −5.9x | −0.6x | |
PEG Ratio | 0.20 | −0.21 | 0.00 | |
Price/Book | 19.9x | 2.8x | 2.6x | |
Price / LTM Sales | 4.2x | 3.9x | 3.3x | |
Upside (Analyst Target) | 14.5% | 19.7% | 38.8% | |
Fair Value Upside | Unlock | 13.2% | 5.4% | Unlock |